Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2015 · 10-Q
Revenue$38.32M$38.32M+20.4% vs Q1 2014 Net Income-$4.61M-$4.61MN/M vs Q1 2014 EPS Diluted-$30.76-$30.76N/M vs Q1 2014 Gross Profit$543,000−89.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$5,617,000N/M Free Cash Flowderived-$6,081,000N/M Margins · derivedGross margin1.4%−14.7 pt vs Q1 2014
Operating margin-16.0%−14.7 pt vs Q1 2014
Net margin-12.0%−7.0 pt vs Q1 2014
ended Mar 31, 2015 · filed May 12, 2015 · 42 d after period end